Congress Passes Genetic Information Nondiscrimination Act

Monday, May 12, 2008

SHERMAN OAKS - (May 1, 2008) - A bill that would prohibit discrimination by health insurers and employers based on the information that people carry in their genes won final approval in Congress on Thursday by an overwhelming majority. Click here to read the press release.

Spondylitis Association Participates in Study That Uncovers Two Genes Related to Disabling Form of Arthritis

Monday, October 21, 2007

SHERMAN OAKS - (October 21, 2007) - A collaborative effort by an international team of researchers in the U.K., Australia and the U.S has led to the discovery of two genes that cause ankylosing spondylitis, a potentially disabling inflammatory disease. Click here to read the press release.

The Spondylitis Association of America Appoints Karrie A. Shogren, PhD to its Board of Directors

Monday, Semptember 17, 2007

SHERMAN OAKS, CALIF. (September 10) -- The Spondylitis Association of America (SAA), the first and largest nonprofit resource in the U.S. for people affected by the rheumatic disease Ankylosing Spondylitis, has appointed Karrie A. Shogren, PhD, to its Board of Directors. Beginning July 1, Dr. Shogren has expanded her commitment to SAA by joining its governing board. Click here to read the press release.

PRESS RELEASE: The Spondylitis Association of America Appoints John D. Reveille, MD to its Board of Directors

Monday, July 16, 2007

SHERMAN OAKS, CALIF. (July 9) -- The Spondylitis Association of America (SAA), the first and largest nonprofit resource in the U.S. for people affected by the rheumatic disease Ankylosing Spondylitis, has appointed John D. Reveille, M.D., to its Board of Directors. Beginning July 1, Dr. Reveille brings his 20 plus years of experience and expertise in spondylitis research and treatment to SAA's governing board. Click here to read the press release.

PRESS RELEASE: Humira Approved for Ankylosing Spondylitis

Monday, July 31, 2006

ABBOTT PARK, Ill., July 31, 2006 - Abbott announced today that the U.S. Food and Drug Administration (FDA) approved HUMIRA® (adalimumab) for reducing signs and symptoms in patients with active ankylosing spondylitis (AS). Click here to read the press release.

PRESS RELEASE: ENBREL SureClick(tm) Autoinjector Approved

Friday, June 16, 2006

The FDA has approved the ENBREL SureClick(tm) autoinjector, the first and only autoinjector for psoriatic and rheumatic diseases. Click here to read the press release.

PRESS RELEASE: Humira ® Approved for Use in Psoriatic Arthritis

Tuesday, October 4, 2005

Abbott has announced that the FDA has approved it's biologic medication, Humira, for use in treating Psoriatic Arthritis, one of the disease that make up the family of diseases known as spondylitis. Although not approved by the FDA for ankylosing spondylitis, it has been prescribed off-label. Click here to read the press release.

Hurricane Katrina: Access to REMICADE ®

Wednesday, September 21, 2005

Centocor, Inc. is committed to ensuring patients and caregivers displaced by the devastation caused by Hurricane Katrina continue to have access to REMICADE® (infliximab) therapy, regardless of their situation or location. Click here to read the press release.

FDA Approves Celebrex ® for AS

Monday, August 1, 2005

NEW YORK, Aug. 1 - Pfizer Inc said today that the U.S. Food and Drug Administration has approved the company's selective COX-2 inhibitor Celebrex (celecoxib) for the relief of the signs and symptoms associated with ankylosing spondylitis, a form of arthritis that affects the spine. Celebrex continues to be an important treatment option for patients suffering from the pain of osteoarthritis and adult rheumatoid arthritis, acute pain, menstrual pain, and as a treatment for familial adenomatous polyposis, a rare condition that leads to colon cancer. Click here to read the press release.

Arthritis of the Spine Often Overlooked in Children

First, National Life Impact Study of Ankylosing Spondylitis Identifies Need for Parent, Physician Awareness

Wednesday, June 15, 2005

When kids or teens experience aching joints and stiffness it may be more than growing pains. It may be arthritis of the spine and other joints (ankylosing spondylitis), which researchers report can often go undiagnosed for years and years, leading to serious problems in adulthood. Click here to read the press release.

FDA Approves Remicade ® for Psoriatic Arthritis

Tuesday, May 17, 2005

Centocor, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved REMICADE® (infliximab) to reduce the signs and symptoms of active arthritis in patients with psoriatic arthritis. Click here to read the press release.

FDA Approves REMICADE ® for Patients with Ankylosing Spondylitis

Wednesday, December 22, 2004

Centocor, Inc., maker of the TNF-a Inhibitor drug, Remicade (Infliximab) has announced that the FDA has approved the drug for use in treating ankylosing spondylitis (AS). Remicade now joins the Amgen & Wyeth medication, Enbrel (etanercept) as the only other TNF-a Inhibitor to be approved for the treatment of AS. Click here to read the press release.

Centocor Announces FDA Acceptance of Supplimental Biologics License Application for Remicade ® to Treat Ankylosing Spondylitis

Tuesday, April 20, 2004

Centocor, Inc., announced today that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for the use of REMICADE® (infliximab) for the treatment of ankylosing spondylitis (AS), a chronic, progressive and debilitating inflammatory disease that often leads to stiffening and subsequent fusion of the spine. Click here to read the press release.

Childhood Onset Ankylosing Spondylitis Is Substantially More Disabling Than Adult Onset Disease, According to SAA Survey

Tuesday, October 28, 2003

In data presented today at the 67th annual meeting of the American College of Rheumatology, the Spondylitis Association of America (SAA) said that people who develop ankylosing spondylitis (AS) in childhood appear to have more severe functional impairment than people who develop AS as adults. The research was presented by Dr. Millicent A Stone, MD, Assistant Professor of Medicine, University of Toronto. Click here to read the press release.

SAA Applauds Senate for Passage of Genetics Testing Non-Discrimination Bill; Calls for Quick Passage by the House

Tuesday, October 14, 2003

The Spondylitis Association of America (SAA) applauds the U.S. Senate, which today approved language that would prohibit insurers from raising premiums or denying coverage based on the results of genetic testing. Senate bill S.1053 would also make it illegal for insurers to require such tests. Click here to read the press release.

SAA Recognizes ENBREL Approval by FDA as Milestone in AS Treatment

Thursday, July 24, 2003

The Spondylitis Association of America (SAA) today released the following statement regarding Enbrel™ (etanercept), the first biologic medicine approved to treat ankylosing spondylitis (AS) in the United States. Click here to read the press release.

Ankylosing Spondylitis Guidance Document Forwarded to FDA

Wednesday, July 2, 2003

The Spondylitis Association of America (SAA) today announced that the organization, along with prominent researchers from around the world, has forwarded a draft copy of the proposed "Ankylosing Spondylitis Guidance Document" to the U.S. Food and Drug Administration (FDA) for review. SAA and the Ankylosing Spondylitis Assessment Working Group (ASAS), a professional group, joined together to spear-head the project. Click here to read the press release.